How to Test the Biocompatibility of a Material

Verification of the biocompatibility of medical-grade TPE materials must comply with authoritative international standards. The safety of materials in contact with the human body is evaluated through systematic biological tests, focusing on key indicators such as cytotoxicity, sensitization, and irritation, to ensure that the material poses no potential biological risks in specific medical scenarios.

Clarify the Standard Framework for biocompatibility testing

Internationally, the ISO 10993 series of standards serves as the core, while the corresponding domestic standard is the GB/T 16886 series. The technical requirements of the two are basically consistent. Both classify medical devices according to the type of contact with the human body (surface contact, external access, implantation) and contact duration (short-term <24 hours, long-term 24 hours–30 days, permanent >30 days). Different categories require matching test items. For medical-grade TPE materials, the test scope must be determined based on their application scenarios (e.g., protective gloves for short-term skin contact, soft tissue repair devices for long-term implantation) to avoid omitting critical items.

Core Test Items: Comprehensive Coverage of Biological Risks

1. cytotoxicity testing: It is a basic threshold. In accordance with iso 10993-5, the cell survival rate is evaluated via the extraction method (co-culturing the TPE material extract with L929 cells), requiring a relative proliferation rate >70% without obvious cell lysis or morphological abnormalities, ensuring that the material does not exert toxic effects on cells.

2. sensitization testing: It shall be conducted in accordance with iso 10993-10. The Guinea Pig Maximization Test (GPMT) or Local Lymph Node Assay (LLNA) is used to assess whether the material induces allergic reactions. Test results must show no or very slight sensitization to prevent skin allergies in patients or medical staff after contact.

3. Irritation Testing: It targets TPE products in contact with skin and mucous membranes. Through rabbit skin irritation test or eye irritation test, the test observes whether erythema, edema and other reactions occur at the contact site of the material extract, requiring no irritation or mild irritation with rapid recovery.

Special Tests for Long-Term Contact or Implantation Scenarios

4. Acute Systemic Toxicity Testing (ISO 10993-4): It is performed by injecting the material extract into mice intravenously or intraperitoneally, observing for toxic symptoms or death within 7 days to evaluate the systemic toxicity risk of material degradation products.

5. Subchronic Toxicity Testing: It requires an extended observation period (usually 28 days) to assess the effects of long-term material contact on organ function and blood indicators, applicable to long-term implantable TPE products.

6. Genotoxicity Testing (ISO 10993-3): It detects whether the material causes gene mutations or chromosomal abnormalities through the AMES test, chromosome aberration test, etc., to avoid potential carcinogenic risks. This test is mandatory especially for implantable TPE materials.

Strictly Follow Standardized Test Procedures

First, material pre-treatment is carried out: specimens are prepared per standard requirements (e.g., cut to specified dimensions, surface contaminants removed), and appropriate extraction conditions (e.g., extract type, temperature, time) are selected based on material properties to ensure the extract truly reflects the in vivo degradation of the material. Testing must be completed by JJR, a third-party laboratory with CNAS or CMA accreditation, using standardized cell lines, laboratory animals and detection methods to guarantee the objectivity and repeatability of results. Negative controls (e.g., high-density polyethylene) and positive controls (e.g., phenol solution) shall be set during testing to verify the effectiveness of the test system through comparison.

Comprehensive Interpretation of Test Results

Interpretation of test results requires comprehensive judgment combined with application scenarios. If a single test fails, the cause shall be analyzed, which may result from precipitation of additives in the material formulation (e.g., lubricants, antioxidants), and the formulation shall be adjusted before retesting. For multi-component TPE materials, the biocompatibility of the base material and each additive must be tested separately to avoid the risk of "overall qualification but local non-compliance". If the material is used for special populations (e.g., infants, immunocompromised patients), additional targeted tests shall be conducted, such as cytokine release testing to evaluate immune responses, ensuring the safety of the material in sensitive populations.

Confirm Biocompatibility Through ComplianCE certification

Finally, biocompatibility must be confirmed through compliance certification. The test report must meet medical device registration requirements. Domestic submission requires test data recognized by NMPA, while exports must comply with relevant EU CE or US FDA requirements. Meanwhile, material manufacturers shall establish biocompatibility files, including compliance certificates from raw material suppliers and sampling inspection reports for each batch of materials, to ensure the sustained stability of biocompatibility and provide a complete evidence chain for the safe application of medical-grade TPE materials.